Corporate, Microbial genomics

Illumina statement on novel coronavirus

Illumina has enacted precautionary measures focusing on the health and safety of our employees, families, customers and communities

Illumina statement on novel coronavirus
March 17, 2020

With the global spread of SARS-CoV-2, Illumina has enacted precautionary measures focusing on the health and safety of our employees, families, customers and communities. To help protect Illumina employees and business continuity, we have proactively implemented efforts including limiting travel and attendance at meetings and conferences, and allowing employees to work remotely, where possible. We are closely monitoring the situation and will update our action plan to protect employees, keep customers running and support efforts to minimize the spread of the virus. To date, we have not experienced sustained supply chain or other operational delays. We will continue to monitor and update as the situation evolves, balancing the safety of our employees and the needs of our customers. 

 

 

Recent articles

Leveraging proteomics to understand rare melanomas
Video: Leveraging proteomics to understand rare melanomas
Celebrating milestones and the future of oncology in China
Celebrating milestones and the future of oncology in China
A normal life with LQTS is possible—just ask the Hansens
A normal life with LQTS is possible—just ask the Hansens